Quick Answer
Cell Source, Inc. reported Diluted EPS of $0.17 per share (loss) for fiscal year 2023.
Cell Source, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$0.17 | +5.6% |
| 2022 | -$0.18 | +5.3% |
| 2021 | -$0.19 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | -$0.04 | +0.0% | +0.0% |
| June 30, 2024 | -$0.04 | +0.0% | +0.0% |
| March 31, 2024 | -$0.04 | +20.0% | +0.0% |
| September 30, 2023 | -$0.04 | +0.0% | +0.0% |
| June 30, 2023 | -$0.04 | +0.0% | +20.0% |
| March 31, 2023 | -$0.05 | +0.0% | -25.0% |
| September 30, 2022 | -$0.04 | — | +0.0% |
| June 30, 2022 | -$0.04 | — | +20.0% |
- Cell Source, Inc. showed an increase of +5.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, Cell Source, Inc.’s diluted eps has grown by 10.5% (from $0.19 per share (loss) to $0.17 per share (loss)).
- The most recent figure is from Cell Source, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on June 24, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: